Study protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours
Open Access
Abstract
Introduction Caregivers of patients with primary malignant brain tumours experience substantial psychological distress while caring for someone with a progressive, life-limiting neurological illness. However, there are few interventions aimed at addressing the psychosocial needs of this population. We developed and are testing a population-specific, evidence-based, telehealth intervention (NeuroCARE) to reduce anxiety symptoms and improve psychosocial functioning in this caregiver population. Methods and analysis This study is a non-blinded, randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours receiving care at the Massachusetts General Hospital Cancer Center or Dana-Farber Cancer Institute. We will enrol 120 caregivers who screen positive for heightened anxiety. Participants will be randomised 1:1 to the NeuroCARE intervention or a usual care control condition. Caregivers assigned to NeuroCARE will complete six individual telehealth sessions with a trained behavioural health specialist over 12 weeks. Caregivers randomised to the control condition will receive usual care, including possible referral to social work or other appropriate resources. Participants will complete self-report questionnaires at baseline and 11 weeks and 16 weeks postrandomisation. The primary outcome is anxiety symptoms at 11 weeks among NeuroCARE participants, compared with usual care. Secondary outcomes include caregiver-reported depressive symptoms, quality of life, caregiver burden, caregiving self-efficacy, perceived coping skills and post-traumatic stress disorder symptoms. We also will explore potential mediators of the NeuroCARE effect on caregiver anxiety symptoms. Ethics and dissemination The study is funded by a Career Development Award from Conquer Cancer, the American Society of Clinical Oncology Foundation (award number 2019CDA-7743456038) and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #19-250 V.10.1). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be presented at scientific meetings and in peer-reviewed journals. Trial registration number NCT04109209Keywords
Funding Information
- American Society of Clinical Oncology (2019CDA-7743456038)
This publication has 35 references indexed in Scilit:
- Reenvisioning Clinical ScienceClinical Psychological Science, 2013
- Health-related quality of life of significant others of patients with malignant CNS versus non-CNS tumors: a comparative studyJournal of Neuro-Oncology, 2013
- The challenges and suffering of caring for people with primary malignant glioma: qualitative perspectives on improving current supportive and palliative care practicesBMJ Supportive & Palliative Care, 2013
- The CareGiver Oncology Quality of Life questionnaire (CarGOQoL): Development and validation of an instrument to measure the quality of life of the caregivers of patients with cancerEuropean Journal of Cancer, 2012
- Usual and Unusual CarePsychosomatic Medicine, 2011
- Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics supportJournal of Biomedical Informatics, 2009
- A Brief Measure for Assessing Generalized Anxiety DisorderArchives of internal medicine (1960), 2006
- Anxiety, depression, and quality of life in caregivers of patients with cancer in late palliative phaseAnnals of Oncology, 2005
- Adjusting for multiple testing—when and how?Journal of Clinical Epidemiology, 2001
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983